Post-Traumatic Stress Disorder (PTSD) Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments - Research and Markets

DUBLIN--()--The "Post-Traumatic Stress Disorder (PTSD) Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments" report has been added to Research and Markets' offering.

Disease Overview

Post-traumatic stress disorder (PTSD) is a neurological disorder that develops in people who have experienced a scary or a dangerous event. PTSD can occur in a person at any age.

According to the National Center of PTSD, around seven to eight out of 100 individuals experience PTSD at some point in their lives in the U.S. PTSD generally occurs more often in women than men. It is natural for a person to be feared during or after a traumatic situation, this fear triggers alteration of many split-seconds in the body to defend against danger.

Fight-or-flight response is one of the essential body's defensive mechanism that protects body in adverse situations. Most of the people recover from traumatic situation naturally, but those who continue to experience problems are diagnosed with PTSD.

Pipeline Analysis

Considerable growth is expected in the PTSD therapeutic pipeline, attributed to increasing prevalence of the disease, further aggravated by stressful lifestyle.

Funds from the various non-profit organization such as, PTSD Foundation of America, Anxiety and Depression Association of America, Defense Centers of Excellence for Psychological Health & Traumatic Brain Injury. are supporting the development of therapeutic pipeline of the disease.

Increasing collaboration between educational institutes and pharmaceutical companies is also one of the factors for growth of PTSD pipeline. In addition, many patents have also been approved during the development of the drug candidates for the treatment of the disease.

Key Topics Covered:

1. Research Background

2. Research Methodology

3. Executive Summary

4. Pipeline Outlook

5. PTSD Therapeutics Pipeline Analysis By Phase (2017)

6 Competitive Landscape

7 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/8wlstg/posttraumatic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Clinical Trials, Mental Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Clinical Trials, Mental Disorders Drugs